COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.
Whittle
B J
BJ
William Harvey Research Institute St Bartholomew's and the Royal London School of Medicine and Dentistry Charterhouse Square, London EC1M 6BQ, UK. B.J.Whittle@mds.qmw.ac.uk
D000818:Animals; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000201:enzymology; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D007413:Intestinal Mucosa / Q000201:enzymology; D007527:Isoenzymes / Q000502:physiology; D008565:Membrane Proteins; D051379:Mice; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects* / Q000502:physiology; D016896:Treatment Outcome
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C496512:Ptgs1 protein, mouse